[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Roche reported positive Phase III Krascendo 1 results for divarasib in previously treated KRAS G12C NSCLC, showing statistically significant, clinically meaningful improvements in both progression-free survival and overall survival versus sotorasib/adagrasib. The primary and key secondary endpoints were met, and the safety profile was consistent with prior data, with no new findings and common treatment-related events described as manageable and reversible. Overall, the read-through is a potential step-change in efficacy for this KRAS G12C franchise and could drive favorable repricing of the company’s oncology pipeline.

Analysis

This is more important for Roche’s oncology franchise narrative than for near-term earnings. A clean OS/PFS beat in a targeted lung cancer setting can shift sell-side valuation from “pipeline optionality” to “credible franchise extension,” which matters because the market is paying for durability, not just one more asset. The likely first-order winner is RHHBY; the second-order winner is anyone with exposure to Roche’s broader lung-cancer combo platform if this becomes the preferred KRAS backbone.

The losers are AMGN and BMY, but the real pressure is on future KRAS commercial share and trial economics rather than current revenue. If divarasib is meaningfully better tolerated, physicians will favor it in later lines and it may become the default comparator for next-gen KRAS combinations, raising the bar for emerging competitors. That can compress the probability-adjusted value of smaller biotech KRAS programs even before any direct head-to-head data.

The contrarian risk is that the market overvalues a phase III win before label, pricing, and sequencing are clear. In 1-3 months the catalyst is regulatory filing/meeting and analyst model updates; in 6-18 months the question is whether Roche can convert this into combo and earlier-line expansion, which is what would justify multiple expansion. Falsifier: if the benefit is modest versus standard of care, if safety creates discontinuation in real-world use, or if AMGN/BMY launch combo/data that narrows the efficacy gap, the premium should fade.

Key Decisions for Investors

• Long RHHBY on a 1-3 month horizon; treat this as a sentiment + franchise-quality rerating trade rather than an immediate EPS story. Risk/reward improves on any post-news consolidation, with downside limited unless safety or follow-up data disappoint.
• Pair trade: long RHHBY / short BMY or AMGN for 1-6 months if the market starts pricing KRAS share shift. The thesis is that Roche gets multiple expansion while the incumbents face commercial durability risk in the KRAS lung-cancer niche.
• If you want lower single-name risk, buy RHHBY call spreads out 3-6 months into regulatory filing or congress-season data follow-up. Best entry is after the initial gap if volume fades; thesis breaks if management gives a cautious launch/label message.
• Watch small-cap KRAS/oncology names for relative weakness over 1-3 months; use them as a basket short only if additional combo data confirm Roche becomes the preferred backbone. Missing data: real-world tolerability and treatment sequencing.
• Set an alert for any Roche commentary on first-line or combo development; that is the point where this becomes a structural growth story and the stock can re-rate beyond a single product readout.